Ju DongYangMD

Gastroenterology • West Hollywood, CA

Biliary Tract Disease, Gastrointestinal Cancer, Hepatology & Liver Transplantation

Physician

Join to view full profile

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yang's full profile

Already have an account?

Office
8700 Beverly Blvd
West Hollywood, CA 90048
Phone+1 310-423-6000

Fax+1 310-423-2356

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Transplant Hepatology, 2018 - 2018
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2014 - 2017
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2011 - 2014
Mayo Clinic College of MedicinePost-Doctoral Fellowship, 2009 - 2011
OtherClass of 2005, MD

Certifications & Licensure

CA State Medical License 2018 - 2026
MN State Medical License 2014 - 2019
AR State Medical License 2013 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Clinical Trials

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Start of enrollment: 2021 May 11
RECRUITING
PHASE2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Letter: Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Liver Cancer-Results From the Global Burden of Disease Study 2021. Authors' R...
Pojsakorn Danpanichkul, Donghee Kim, Markos Kalligeros, Amit G Singal, Ju Dong Yang
Alimentary Pharmacology & Therapeutics. 2025-03-01
4 citations
Alcohol-Related Liver Disease, Followed by Metabolic Dysfunction-Associated Steatotic Liver Disease, Emerges as the Fastest-Growing Aetiologies for Primary Liver Cance...
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, Michael B Fallon, Chawinthorn Vuthithammee
Alimentary Pharmacology & Therapeutics. 2025-03-01
Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States-Author's Reply.
Pojsakorn Danpanichkul, Donghee Kim, Chun Wei Pan, Amit G Singal, Ju Dong Yang
Alimentary Pharmacology & Therapeutics. 2025-03-01

Press Mentions

Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver CancerAugust 19th, 2024
Acceptable Liver Transplant Outcomes Seen After ICI Therapy for Liver CancerAugust 19th, 2024
Study: Transplant Possible After Immunotherapy for Advanced Liver Cancer PatientsAugust 8th, 2024